#### In the claims:

1. (Currently amended) A compound of Formula I:

$$(CR^{1a}_{2})_{s} - Y$$
 $(CR^{1b}_{2})_{t} - Z$ 
 $R^{5}$ 
 $R^{2}$ 
 $R^{6}$ 
 $R^{2}$ 
 $R^{6}$ 
 $R^{7}$ 

wherein:

R1a and R1b are independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- $OR^3$ ,
- 4)  $N(R^3)_2$ ,
- 5) unsubstituted or substituted aryl,
- 6) unsubstituted or substituted heterocycle, and
- 7) unsubstituted or substituted C3-C10 cycloalkyl;

R1c is independently selected from:

- 1) hydrogen,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- $OR^3$ ,
- 4)  $N(R^3)_2$ ,
- 5) C3-C10 cycloalkyl,
- 6) aryl, and
- 7) heterocycle;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>2</sup> is independently selected from:

- 1)  $N(R^3)_2$ , and
- $OR^3$ ;

R<sup>3</sup> is independently selected from:

- 1) hydrogen, and
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl;

said alkyl is optionally substituted with at least one substituent selected from  $R^7$  with OR, where R is H or  $C_1$ - $C_{10}$  alkyl;

R<sup>5</sup> is independently selected from:

- 1) hydrogen,
- 2) halogen,
- $-(CR^{1}c_2)_nOR^3$ ,
- 4)  $-(CR^{1}c_{2})_{n}R^{6}$ ,
- 5)  $-C(O)OR^3$ ,
- 6)  $-C(O)R^3$ ,
- 7)  $-C \equiv CR^3$ ,
- $_{8)}$   $_{-}R^{3}C = C(R^{3})_{2}$
- 9)  $-OS(O)_mR6$ ,
- 10) -NO<sub>2</sub>,
- 11)  $-(CR^{1}c_{2})_{n}N(R^{3})_{2}$ ,
- 12)  $-N(R^3)C(O)R^3$ ,
- 13)  $-N(R^3)S(O)_mR^6$ ,
- 14)  $-(CR^{1}c_{2})_{n}NR^{3}(CR^{1}c_{2})_{n}C(O)NR^{3}c_{2}$
- 15)  $-O(CR^{1}c_{2})_{n}C(O)N(R^{3})_{2}$ ,
- 16)  $-O(CR^{1}c_{2})_{n}C(O)OR^{3}$ ,
- 17)  $-NR^3(CR^{1}c_2)_nN(R^3)_2$ ,
- 18)  $-(CR^{1}c_{2})_{n}NR^{3}R^{6}OR^{3}$ ,
- 19)  $-S(O)_{m}R^{6}$ ,
- 20)  $-S(O)_mN(R^3)_2$ ,
- 21) -CN,
- 22)  $-(CR^{1}c_{2})_{n}N(R^{3})(CR^{1}c_{2})_{n}R^{6}$ , and

# 23) $-(CR^{1}c_{2})_{n}C(O)N(R^{3})_{2};$

R6 is independently selected from:

- 1) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) C3-C10 cycloalkyl,
- 3) aryl, and
- 4) heterocycle;

said, alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from  $\mathbb{R}^7$ ;

## R<sup>7</sup> is independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) unsubstituted or substituted C3-C10 cycloalkyl,
- 4) unsubstituted or substituted aryl,
- 5) halogen,
- $OR^3$ ,
- 7) CF<sub>3</sub>,
- 8) unsubstituted or substituted heterocycle,
- 9)  $S(O)_m N(R^3)_2$ ,
- 10)  $C(O)OR^3$ ,
- 11)  $C(O)R^3$ ,
- 12) CN,
- 13)  $C(O)N(R^3)_2$ ,
- 14)  $N(R^3)C(O)R^3$ ,
- 15)  $S(O)_mR^6$ , and
- 16) NO2;

# Y and Z are independently selected from:

- 1) hydrogen,
- 2) R6,
- $OR^3$ ,
- 4)  $N(R^3)_{2}$
- 5)  $C(O)OR^3$ ,

- 6)  $C(O)N(R^3)_2$ ,
- 7)  $C(O)R^3$ ,
- 8) halogen,
- 9)  $N(R^3)(CR^1c_2)_nC(O)N(R^3)_2$ ,
- 10) S(O)<sub>m</sub>N(R<sup>3</sup>)<sub>2</sub>,
- 11)  $N(R^3)C(O)OR^3$ ,
- 12)  $N(R^3)S(O)_mR^6$ ,
- 13)  $N(R^3)C(O)R^3$ ,
- 14)  $N(R^3)(CR^{1}c_2)_nR^3$ ,
- 15)  $S(O)_m R^6$ ,
- 16) R<sup>6</sup>S(O)<sub>m</sub>N(R<sup>3</sup>)<sub>2</sub>,
- 17) R6S(O)<sub>m</sub>R6,
- 18)  $N(R^3) S(O)_m (CR^{1c_2})_n R^6$ ,
- 19)  $N(R^3)S(O)_mR^6OR^3$ ,
- 20)  $N(R^3)C(O)N(R^3)2$ ,
- 21)  $N(R^3)C(O)R^6OR^3$ ,
- (22) N(R3)(CR1c<sub>2</sub>)<sub>n</sub>R6OR3,
- 23)  $N(R^3)OR^3$ , and
- 24)  $N(R^3)S(O)_mR^6NO_2;$

m is independently 0, 1 or 2; n is independently 0 to 6; s is 0 to 6; t is 0 to 6; w is 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Currently amended) The compound according to Claim 1,

wherein:

Rla and Rlb are independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,

- 3) unsubstituted or substituted aryl,
- 4) unsubstituted or substituted heterocycle, and
- 5)  $OR^3$ ;

R1c is independently selected from:

- 1) hydrogen,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3)  $OR^3$ ,
- 4)  $N(R^3)_2$ ,
- 5) aryl, and
- 6) heterocycle;

said alkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>2</sup> is:

- 1)  $OR^3$ , or
- 2)  $N(R^3)_2$ ;

R<sup>3</sup> is independently selected from:

- 1) hydrogen, and
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl;

said alkyl is optionally substituted with at least one substituent selected from R<sup>7</sup>OR, where R is H or C<sub>1</sub>-C<sub>10</sub> alkyl;

R<sup>5</sup> is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3)  $-OR^3$ ,
- 4)  $-C(O)OR^3$ ,
- 5)  $-C(O)R^3$ ,
- 6)  $-C \equiv CR^3$ ,
- 7)  $-R^3C = C(R^3)_2$ ,
- 8)  $-OS(O)_mR^6$ ,
- 9) -NO<sub>2</sub>,

- 10)  $-N(R^3)_2$
- 11)  $-N(R^3)C(O)R^3$ ,
- 12)  $-N(R^3)S(O)_mR^6$ ,
- 13)  $-(CR^{1c_2})_nNR^3(CR^{1c_2})_nC(O)NR^3_2$ ,
- 14)  $-O(CR^{1}c_{2})_{n}C(O)N(R^{3})_{2}$ ,
- 15)  $-O(CR^{1}c_2)_nC(O)OR^3$ ,
- 16)  $-NR^3(CR^{1}c_2)_nN(R^3)_2$ ,
- 17)  $-(CR^{1}c_{2})_{n}NR^{3}R^{6}OR^{3}$ ,
- 18)  $-S(O)_{m}R^{6}$ ,
- 19)  $-S(O)_mN(R^3)_{2}$ ,
- 20) -CN, and
- 21)  $-(CR^{1}c_{2})_{n}N(R^{3})(CR^{1}c_{2})_{n}R^{6};$

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Currently Amended) The compound according to Claim 2,

wherein:

 $R^{1a}$  and  $R^{1b}$  are independently selected from hydrogen, unsubstituted or substituted  $C_1$ - $C_{10}$  alkyl,  $OR^3$ , and unsubstituted or substituted aryl;

R1c is independently selected from:

- 1) hydrogen,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3)  $OR^3$ , and
- 4) aryl;

said alkyl and aryl is optionally substituted with at least one substituent selected from R7;

R<sup>2</sup> is:

- 1)  $OR^3$ , or
- 2)  $N(R^3)_2$ ;

R<sup>5</sup> is independently selected from:

- 1) hydrogen,
- $2) \quad (CR^{1}c_{2})_{n}R^{6},$

- 3) halogen,
- 4)  $-(CR^{1}c_{2})_{n}OR^{3}$ ,
- 5)  $-C(O)OR^3$ ,
- 6)  $-C(O)R^3$ ,
- 7)  $-C \equiv CR^3$ ,
- 8)  $-R^3C = C(R^3)_2$ ,
- 9)  $(CR_{1}c_{2})_{n}C(O)N(R_{3})_{2}$ , and
- 10)  $(CR^{1}c_{2})_{n}N(R^{3})_{2};$

#### Y is:

- 1) hydrogen,
- 2) R6,
- 3)  $OR^3$ ,
- 4)  $C(O)R^3$ ,
- 5)  $C(O)N(R^3)_2$ , or
- 6)  $N(R^3)_2$ ;

## Z is:

- 1) hydrogen,
- 2) R6,
- $OR^3$ ,
- 4)  $N(R^3)_2$ ,
- 5)  $C(O)OR^3$ ,
- 6)  $C(O)N(R^3)_2$ ,
- 7)  $C(O)R^3$ ,
- 8) halogen,
- 9)  $N(R^3)(CR^{1}c_2)_nC(O)N(R^3)_2$ ,
- 10)  $S(O)_mN(R^3)_2$ ,
- 11)  $N(R^3)C(O)OR^3$ ,
- 12)  $N(R^3)S(O)_mR^6$ ,
- 13)  $N(R^3)C(O)R^3$ ,
- 14)  $N(R^3)(CR^{1}c_2)_nR^3$ , or
- 15)  $S(O)_m R6$ ;

or a pharmaceutically acceptable salt or stereoisomer thereof.

- 4. (Previously presented) A compound selected from:
- 5-Chloro-3-[(methylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 3-(Aminosulfonyl)-5-chloro-1*H*-indole-2-carboxamide;
- 5-Bromo-3-({methyl[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3 yl)methyl] amino} sulfonyl)-1H-indole-2-carboxamide;
- 3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-iodo-1*H*-indole-2-carboxamide;
- 3-[(Dimethylamino)sulfonyl]-5-methoxy-1H-indole-2-carboxamide;
- 5-Chloro-3-{[(2-phenethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(benzylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(cyclohexylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(1-naphthylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(3-phenylpropyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(propylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(butylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(pentylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[ethyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(diethylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(iso-propylamino)sulfonyl]-1*H*-indole-2-carboxamide;

- 5-Chloro-3-[(cyclobutylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(cyclopentylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(4-chlorophenyl)amino}sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(3-chlorophenyl)amino}sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(2-chlorophenyl)amino}sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(4-chlorophenyl)methylamino}sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(3-chlorophenyl)methylamino}sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(2-chlorophenyl)methylamino}sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(tert-butylamino)sulfonyl]-1H-indole-2-carboxamide;
- (±)-5-Chloro-3-[(pyrrolidin-3-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(piperidin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(1-methyl-1*H*-benzimidazol-2-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(benzamideamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(5-aminotetrazole)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(pyridin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(pyridin-2-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- $5-Chloro-3-\{[(2-methyoxyethyl)amino] sulfonyl\}-1 \\ H-indole-2-carboxamide;$
- 5-Chloro-3-[(dimethylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- $3-(\{[2-(Aminosulfonyl)ethyl]amino\} sulfonyl)-5-chloro-1 \\ H-indole-2-carboxamide;$
- 5-Chloro-3-{[(2-hydroxyethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

```
5-Chloro-3-{[(2-morpholin-4-ylethyl)amino]sulfonyl}-1H-indole-2-carboxamide;
5-Chloro-3-{[(2-methoxyethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;
5\text{-}Bromo-3-[(\{[2\text{-}(2\text{-}acetamide)amino}]\text{ethyl}\}\text{amino})\text{sulfonyl}]-1H\text{-}indole-2-carboxamide};
N-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}-N-methyl-\beta-alaninamide;
5-Bromo-3-[(methylamino)sulfonyl]-1H-indole-2-carboxamide;
Ethyl N-{[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl} N-methyl-β-alaninate;
5-Bromo-3-{[cyclopropyl(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;
(\pm)-5-Bromo-3-{[methyl(tetrahydrofuran-3-yl)amino]sulfonyl}-1H-indole-2-carboxamide;
5-Bromo-3-({methyl[2-(1H-1,2,4-triazol-1-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;
5-Bromo-3-{[methyl(tetrahydro-2H-pyran-4-yl)amino]sulfonyl}-1H-indole-2-carboxamide;
(\pm)-5-Bromo-3-\{[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl\}-1H-indole-2-carboxamide;
3-({[4-(Aminosulfonyl)benzyl]amino}sulfonyl)-5-bromo-1H-indole-2-carboxamide;
5-Chloro-3-{[iso-propyl(2-methoxyethyl)amino]sulfonyl}-1H-indole-2-carboxamide;
3-{[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl}-5-hydroxy-1H-indole-2-carboxamide;
3-{[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl}-5-methoxy-1H-indole-2-carboxamide;
5-Chloro-3-{[methoxy(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;
(\pm)-5-Chloro-3-\{[(2,3-dihydroxypropyl)(methyl)amino]sulfonyl\}-1H-indole-2-carboxamide;
5-Chloro-3-{[(2-hydroxyethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;
N-{[2-(Aminocarbonyl)-5-chloro-1H-indol-3-yl]sulfonyl}-N-methylglycine;
N-{[2-(Aminocarbonyl)-5-chloro-1'H-indol-3-yl]sulfonyl}-N-methylglycinamide;
5-Bromo-3-({[4-(methylsulfonyl)benzyl]amino}sulfonyl)-1H-indole-2-carboxamide;
3-[({2-[4-(Aminosulfonyl)phenyl]ethyl}amino)sulfonyl]-5-bromo-1H-indole-2-carboxamide;
```

- 3-{[(5-Amino-5-oxopentyl)amino]sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;
- 3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide;
- tert-Butyl 2-({[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl}amino)-ethylcarbamate;
- 3-{[(2-Aminoethyl)amino]sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({ethylsulfonylamino}ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Iodo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1 *H*-indole-2-carboxamide;
- 5-Bromo-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Fluoro-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(4-nitrophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-({[2-({[(4-methoxyphenyl)amino]carbonyl}amino)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;
- $5\text{-}Bromo-3-[(\{3\text{-}[(4\text{-}chlorophenyl)thio]propyl\}amino)sulfonyl]-1}\\H-indole-2-carboxamide;$
- 5-Bromo-3-[({3-[(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1 *H*-indole-2-carboxamide;
- $5\text{-}Bromo-3-[(\{3\text{-}[(4\text{-}chlorophenyl)sulfonyl]propyl}\}amino)sulfonyl]-1\ H-indole-2-carboxamide;$
- $5-Bromo-3-[(\{propylsulfonylamino\}ethylamino)sulfonyl]-1 \emph{$H$-indole-2-carboxamide hydrochloride;}$
- 5-Bromo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

- $5\text{-}Bromo-3\text{-}[(\{2\text{-}[(phenylsulfonyl)amino}]\text{ethyl}\}\text{amino})\text{sulfonyl}]\text{-}1H\text{-}indole-2\text{-}carboxamide};$
- 5-Bromo-3-[({2-[(methylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 3-[({2-[(Benzylsulfonyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(3-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3- $\{[(2-\{[(2,5-dimethoxyphenyl)sulfonyl]amino\}ethyl)amino]sulfonyl\}-1H-indole-2-carboxamide;$
- 5-Bromo-3-{[(2-{[(5-bromo-2-methoxyphenyl)sulfonyl]amino}ethyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-({[2-({[2-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl]amino} sulfonyl)-1 *H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(2-methoxy-5-methylphenyl)sulfonyl]amino}ethyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(4-cyanophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- $5-Bromo-3-\{[(2-\{[(4-chlorophenyl)sulfonyl]amino\}ethyl)amino]sulfonyl\}-1\\ H-indole-2-carboxamide;$
- 5-Bromo-3-{[(2-{[(3,4-dimethoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({3-[(phenylsulfonyl)amino]propyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

- 5-Bromo-3-{[(3-{[(4-methoxyphenyl)sulfonyl]amino}propyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 3-[({3-[(Benzylsulfonyl)amino]propyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;
- $3-[(\{2-[(Aminocarbonyl)amino]ethyl\}amino)sulfonyl]-5-bromo-1 \\ H-indole-2-carboxamide;$
- 5-Bromo-3-{[(2-{[(4-bromophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({2-[(thien-3-ylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(3-chlorobenzyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(2-phenylethyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({2-[(4-methoxybenzoyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({2-[(4-methoxybenzyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({2-[(4-methoxyphenyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({2-[(4-methoxyphenyl)(methylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 3-[({2-[Acetyl(4-methoxyphenyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;
- 5-Iodo-3-{[cyclopropyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Iodo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;

- 5-Bromo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Iodo-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- $(\pm)$ -5-Chloro-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- $(\pm)$ -5-Bromo-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- $(\pm)$ -5-Iodo-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- ( $\pm$ )-5-Chloro-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- (±)-5-Bromo-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- ( $\pm$ )-5-Iodo-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1-H-indole-2-carboxamide;
- $5-chloro-3-\{[methyl(tetrahydro-2H-pyran-4-yl)amino] sulfonyl\}-1H-indole-2-carboxamide;$
- 5-chloro-3-({[1-(2,3-dihydro-1,4-benzodioxin-2-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-chloro-3-[(tetrahydro-2H-pyran-4-ylamino)sulfonyl]-1H-indole-2-carboxamide;
- 5-chloro-3-{[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-chloro-3-({[(3-methyloxetan-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-chloro-3-[(tetrahydrofuran-3-ylamino) sulfonyl]-1 H-indole-2-carboxamide;
- 5-chloro-3-({[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

- 5-chloro-3-({[2-(3-phenyl-1*H*-1,2,4-triazol-5-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;
- 5-chloro-3-({[2-(2-methoxyphenyl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-chloro-3-({[3-(trifluoromethyl)benzyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-chloro-3-({[2-(2,3-dihydro-1*H*-indol-1-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;
- 5-chloro-3-({methyl[(1-methylpiperidin-3-yl)methyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;
- 5-chloro-3-{[(2,3-dihydro-1,4-benzodioxin-2-ylmethyl) amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-{[(3-ethoxypropyl) amino]sulfonyl}-1H-indole-2-carboxamide;
- 3-[({[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}amino) methyl]-1-benzylpyrrolidine;
- $5-bromo3-(\{[(1-benzylpyrrolidin-3-yl)methyl]amino\} sulfonyl)-1 \\ H-indole-2-carboxamide;$
- $5\text{-bromo-}3\text{-}\{[(3\text{-pyridin-}3\text{-ylpropyl})amino] sulfonyl}\}\text{-}1H\text{-indole-}2\text{-carboxamide};$
- $1-[2-(\{[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl\}amino) ethyl]-4-phenylpiperidine;\\$
- 5-bromo-3-{[(3-cyclohexylpropyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-{[(4,4-diphenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- $5\text{-}bromo-3-\{[(3\text{-}butoxypropyl)amino}] sulfonyl\}-1 \\ H\text{-}indole-2-carboxamide};$
- 5-bromo-3-{[(6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-({[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-bromo-3-({[3-(4-tert-butoxyphenyl)propyl]amino} sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-({[4-(4-tert-butoxyphenyl)butyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{[(2-methoxy-1-methylethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(4-phenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-[({2-[(2,6-dichlorobenzyl)thio]ethyl}amino) sulfonyl]-1H-indole-2-carboxamide;

5-bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-[({6-[(4-chlorobenzyl)amino]-6-oxohexyl}amino)sulfonyl]-1H-indole-2-carboxamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.

- 5. (Original) The compound according to Claim 4, that is selected from:
- $5-Chloro-3-\{[ethyl(methyl)amino]sulfonyl\}-1\\ \textit{H-}indole-2-carboxamide$

 $(\pm)$ -5-Bromo-3- $\{[methyl(tetrahydrofuran-3-yl)amino]$ sulfonyl $\}$ -1H-indole-2-carboxamide

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide

 $5-Bromo-3-\{[(2-\{[(4-methoxyphenyl)sulfonyl]amino\}ethyl)amino]sulfonyl\}-1\\ \emph{$H$-indole-2-carboxamide}$ 

 $5\text{-}bromo-3-\{[(3\text{-}butoxypropyl)amino}] sulfonyl\}-1 \\ H\text{-}indole-2-carboxamide}$ 

$$\begin{array}{c} & & \text{CH}_3 \\ & & \text{O} \\ & & \text{S} = \text{O} \\ & & \text{NH}_2 \\ & & \text{N} \\ & & \text{O} \\ & & \text{H} \end{array}$$

 $5\text{-}bromo-3\text{-}(\{[3\text{-}(4\text{-}tert\text{-}butoxyphenyl)propyl]amino}\} sulfonyl)-1H\text{-}indole-2\text{-}carboxamide}$ 

5-chloro-3-( $\{[2-(3-phenyl-1H-1,2,4-triazol-5-yl)ethyl]amino\}$  sulfonyl)-1H-indole-2-carboxamide

or a pharmaceutically acceptable salt or stereoisomer thereof.

6. (Original) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

Serial No. 10/523,286 Case No. 21007YP Page 20

- 7. (Withdrawn) A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.
- 8. (Withdrawn) The method of Claim 7 wherein the protein kinase is an RTK.
- 9. (Withdrawn) The method of Claim 8, wherein the RTK is selected from IR, IGF-1R and IRR.
- 10. (Withdrawn) A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.
- 11. (Withdrawn) A method of Claim 10, wherein the PK-related disorder is an IGF-1R-related disorder selected from:
  - 1) cancer,
  - 2) diabetes,
  - 3) an autoimmune disorder,
  - 4) a hyperproliferation disorder,
  - 5) aging,
  - 6) acromegaly, and
  - 7) Crohn's disease.
- 12. (Withdrawn) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.
- 13. (Withdrawn) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

Serial No. 10/523,286 Case No. 21007YP Page 21

- 14. (Withdrawn) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:
  - 1) an estrogen receptor modulator,
  - an androgen receptor modulator,
  - 3) retinoid receptor modulator,
  - 4) a cytotoxic agent,
  - 5) an antiproliferative agent,
  - 6) a prenyl-protein transferase inhibitor,
  - 7) an HMG-CoA reductase inhibitor,
  - 8) an HIV protease inhibitor,
  - 9) a reverse transcriptase inhibitor, and
  - 10) an angiogenesis inhibitor.
- 15. (Withdrawn) The method of Claim 14, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.
- 16. (Withdrawn) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.
- . 17. (Withdrawn) The method of Claim 16 wherein radiation therapy is also administered.
- 18. (Withdrawn) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.
- 19. (Withdrawn) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.
  - 20. (Canceled)
  - 21. (Canceled)

Serial No. 10/523,286 Case No. 21007YP Page 22

- 22. (Canceled)
- 23. (Canceled)